As for B symptoms and bone marrow involvement, PD-L1+CD20+ % and PD-1+CD20+ CD20+ % had a significant increase in DLBCL patients with B symptoms and bone marrow involvement (p < 0.001, p = 0.001, p < 0.001 and p = 0.001, Figure 3A–D). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.